{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:19Z","timestamp":1791994279387,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.12.009","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T20:52:24Z","timestamp":1736283144000},"page":"841-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines"],"prefix":"10.1016","volume":"8","author":[{"given":"Bhavan Prasad","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpesh","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Luis","family":"Dominguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.12.009_b0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2022.03.027","article-title":"Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria","volume":"82","author":"Rai","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0010","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1464-410X.2012.11341.x","article-title":"Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review","volume":"110","author":"Rai","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.009_b0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bju.15627","article-title":"Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study","volume":"129","author":"Veeratterapillay","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.009_b0020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.12.009_b0025","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0030","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0035","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.12.009_b0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0050","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0055","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","article-title":"Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database","volume":"3","author":"Moschini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/iju.15380","article-title":"Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma","volume":"31","author":"Sasahara","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.euo.2024.12.009_b0075","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.1464-410X.2011.10075.x","article-title":"Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration","volume":"108","author":"Youssef","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.009_b0080","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/jjco\/hys166","article-title":"A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy","volume":"42","author":"Kitamura","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/iju.12884","article-title":"Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: subanalysis of the multi-institutional national database of the Japanese Urological Association","volume":"22","author":"Hara","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/iju.13010","article-title":"Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes","volume":"23","author":"Kobayashi","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0095","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.18632\/oncotarget.21551","article-title":"Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study","volume":"8","author":"Kubota","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2024.12.009_b0100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","volume":"4","author":"Hosogoe","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.12.009_b0105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JU.0000000000000737","article-title":"Efficacy of preoperative chemotherapy for high risk upper tract urothelial carcinoma","volume":"203","author":"Foerster","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/JU.0000000000000172","article-title":"Optimizing the sequence of chemotherapy for upper tract urothelial carcinoma with clinically positive regional lymph nodes","volume":"202","author":"Chakiryan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0115","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Colla Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0120","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s00432-021-03582-x","article-title":"Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC","volume":"147","author":"Lee","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0125","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bju.15346","article-title":"Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study","volume":"128","author":"Hamaya","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.009_b0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/BLC-211515","article-title":"Impact of neoadjuvant chemotherapy for upper tract urothelial carcinoma: a population based analysis","volume":"7","author":"Venkat","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2024.12.009_b0135","doi-asserted-by":"crossref","first-page":"105.e19","DOI":"10.1016\/j.urolonc.2021.07.029","article-title":"Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study","volume":"40","author":"Shigeta","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.903123","article-title":"Survival impact of nephroureterectomy for de novo stage IV nonmetastatic and metastatic upper tract urothelial carcinoma","volume":"9","author":"Lin","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.euo.2024.12.009_b0145","doi-asserted-by":"crossref","first-page":"e9-409.e17","DOI":"10.1016\/j.urolonc.2022.04.015","article-title":"Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: analysis of NCDB registry","volume":"40","author":"Piontkowski","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0150","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2021.12.014","article-title":"Five and ten-year outcomes of neoadjuvant chemotherapy and surgery for high-risk upper tract urothelial carcinoma","volume":"20","author":"Adibi","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2024.12.009_b0155","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/jjco\/hyad118","article-title":"Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study","volume":"53","author":"Takahashi","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.12.009_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.euo.2024.12.009_b0170","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0175","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.12.009_b0180","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.12.009_b0185","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions. Cochrane Book Series."},{"key":"10.1016\/j.euo.2024.12.009_b0190","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.12.009_b0195","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.12.009_b0200","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.12.009_b0205","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/JU.0000000000003085","article-title":"Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients: a multicenter, retrospective, observational study","volume":"209","author":"Pallauf","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2019.09.004","article-title":"Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma","volume":"3","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.009_b0215","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.juro.2007.05.158","article-title":"Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract","volume":"178","author":"Kondo","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0220","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1442-2042.2012.03009.x","article-title":"Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract","volume":"19","author":"Kondo","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0225","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.juro.2015.06.077","article-title":"Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates","volume":"194","author":"Matin","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euros.2023.09.010","article-title":"Location of retroperitoneal lymph node metastases in upper tract urothelial carcinoma: results from a prospective lymph node mapping study","volume":"57","author":"Bobjer","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.12.009_b0235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00345-016-1764-z","article-title":"Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2017.09.015","article-title":"Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer","volume":"5","author":"Dominguez-Escrig","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.12.009_b0245","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00345-019-03020-1","article-title":"Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases","volume":"38","author":"Veccia","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.12.009_b0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","article-title":"Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology guidelines systematic review","volume":"5","author":"Peyronnet","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.12.009_b0255","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/cancers15204926","article-title":"Oncological efficacy of robotic nephroureterectomy vs. open and laparoscopic nephroureterectomy for suspected non-metastatic UTUC\u2014a systematic review and meta-analysis","volume":"15","author":"Rajan","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112400292X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112400292X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:55:31Z","timestamp":1748451331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112400292X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S258893112400292X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}